Adicet Bio Net Income Over Time
| ACET Stock | USD 8.50 0.51 6.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Adicet Bio Performance and Adicet Bio Correlation. Is there potential for Health Care Providers & Services market expansion? Will Adicet introduce new products? Factors like these will boost the valuation of Adicet Bio. If investors know Adicet will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Adicet Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Adicet Bio using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Adicet Bio's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Adicet Bio's market price to deviate significantly from intrinsic value.
Understanding that Adicet Bio's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Adicet Bio represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Adicet Bio's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Adicet Bio and related stocks such as Lite Strategy, IO Biotech, and Tscan Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LITS | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (54.5 M) | (31.8 M) | 17.8 M | (15.9 M) | (18.3 M) | (19.3 M) |
| IOBT | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (12 M) | (67.9 M) | (71.5 M) | (86.1 M) | (95.5 M) | (85.9 M) | (90.2 M) |
| TCRX | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (26.1 M) | (48.6 M) | (66.2 M) | (89.2 M) | (127.5 M) | (114.7 M) | (109 M) |
| ADAG | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (17.3 M) | (16.4 M) | (73.2 M) | (80 M) | (18.9 M) | (33.4 M) | (30.1 M) | (31.6 M) |
| NRXP | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | 66.1 K | 408.4 K | (51.8 M) | (93.1 M) | (39.8 M) | (30.1 M) | (25.1 M) | (22.6 M) | (23.7 M) |
| HOWL | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (14.9 M) | (49.8 M) | (51.6 M) | (37.4 M) | (70.5 M) | (63.5 M) | (60.3 M) |
| IMUX | (5.9 M) | (5.9 M) | (6.7 M) | (32.7 M) | (47.7 M) | (52 M) | (41 M) | (52.1 M) | (41.5 M) | (34.8 M) | (44 M) | (92.8 M) | (120.4 M) | (93.6 M) | (100.5 M) | (90.5 M) | (85.9 M) |
| ACRV | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (16.2 M) | (29.7 M) | (60.4 M) | (80.6 M) | (72.5 M) | (68.9 M) |
| GANX | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (2.2 M) | (3.6 M) | (13.9 M) | (17.6 M) | (22.3 M) | (20.4 M) | (18.4 M) | (19.3 M) |
| CRVO | 200 K | (22.6 M) | (6.9 M) | (2.5 M) | (14.4 M) | (6.7 M) | (18 M) | (1.4 M) | (18.4 M) | (11.8 M) | (14.2 M) | (24.1 M) | (15.6 M) | (2.2 M) | (16.3 M) | (14.7 M) | (13.9 M) |
Adicet Bio and related stocks such as Lite Strategy, IO Biotech, and Tscan Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Adicet Bio financial statement analysis. It represents the amount of money remaining after all of Adicet Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Adicet Bio | ACET |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 131 Dartmouth Street, |
| Exchange | NASDAQ Exchange |
USD 8.5
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.